Company Market News

Takeda Pharmaceutical Co. Ltd. (NYSE: TAK)
9:00 PM UTC, 12/12/25
Last: $14.33 Change: -0.06 %Change: -0.42% Volume: 2,123,444
Takeda Pharmaceutical Says Hema-Quebec to Cover HyQvia for Immunodeficiency Treatment

Back

Last updated: 01/29/2025 9:03:21 AM

09:03 AM EST, 01/29/2025 (MT Newswires) -- Takeda Pharmaceutical (TAK) said Wednesday that the non-profit organization Hema-Quebec will begin reimbursing HyQvia for patients with primary or secondary humoral immunodeficiencies aged two and older starting Jan. 30 in Quebec, Canada.

The company said HyQvia, a subcutaneous immune globulin infusion indicated for immune system deficiencies that increase infection risk, received Health Canada approval for adults in 2022 and pediatric patients in 2024.

http://www.mtnewswires.com
Copyright © 2025 MT Newswires. All rights reserved. MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.




Quotes displayed with 15 minutes delay. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions. Legal Statement. News provided by MT Newswires, a Division of MidnightTrader, Inc. Events Data provided by Wall Street Horizon. ©2021 Wall Street Horizon, Inc.